LDK378 vs 113-
Sounds, on the surface of it, like 378 won't, in many cases(unlike 113), be able to achieve sufficient dose levels without also causing unacceptable toxities.
Therefore, they(378 users) may be forced to attempt combos with something like ganetespib(an Hsp90 inhibitor) to enable efficacy at the lower dosages possible.
Obviously, with the DLT profile starting at 400mgs, efficacy with brain mets at 750mgs is not likely to be useful in most cases.
In addition,(if I remember correctly), 378 hasn't shown efficacy in previously untreated ALK+ patients.
113, on the other hand, is efficacious at much lower dosages(in untreated & pretreated pts) and effective in brain met pts(without significant DLTs).
Therefore, in summary, it seems pretty obvious that 113, on the basis of what we currently know, should be best in class in ALK+ NSCLC.
Of course, we will need to see more data to substantiate the above(but if I'm correct, I believe this process will be about as pro forma as imaginable).
Ditto+ regarding 113 in EGFR.
Regards,
bw
